(ADMA) Announces Submission of RI-002 BLA to FDA

Submission Reinforces Commitment to Commercialize Novel Therapies for Immune Compromised Patients

RAMSEY, N.J., July 31, 2015  — ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment and prevention of certain infectious diseases, announced that it has submitted its Biologics License Application (BLA) to the United States Food and Drug Administration (FDA), seeking marketing authorization for RI-002.

RI-002 demonstrated positive results in a Phase III study in patients with PI, meeting its primary endpoint of no serious bacterial infections (SBI). These results, included in the submission, more than meet the requirement specified by the FDA guidance of ≤ 1 SBI per patient-year.

“The BLA submission for RI-002 is a significant milestone for our growing company,” stated Adam Grossman, President and CEO of ADMA Biologics. “This submission, combined with our recent announcement of obtaining patent protection for RI-002, places ADMA in a rare position as a company poised to transition from development to commercial stage. We believe that RI-002, if approved by the FDA, has great potential to provide meaningful clinical improvement for patients living with PI, as well as offers clinicians a much needed option for their immune compromised patients. Under PDUFA V, the BLA filing fee is $2.3 million. The FDA reviewed ADMA’s small business waiver application and it was approved.”

PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly, affecting approximately 250,000 people in the United States.

The FDA has a 60-day review period to determine whether ADMA’s BLA submission for RI-002 is complete and acceptable for filing.

About RI-002

ADMA’s lead product candidate, RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin (IGIV) derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus (CMV), measles, tetanus, etc.) as well as standardized, high levels of antibodies to respiratory syncytial virus (RSV). On June 30, 2015, ADMA announced that it had received a notice of allowance for a U.S. patent pertaining to RI-002 entitled “Compositions and Methods for the Treatment of Immunodeficiency.” ADMA is pursuing an indication for the use of this specialty IGIV product for treatment of patients diagnosed with primary immune deficiency disease (PIDD). Polyclonal antibodies are the primary active component of IGIV/immuneglobulin products. Polyclonal antibodies are proteins that are used by the body’s immune system to neutralize microbes, such as bacteria and viruses. Data review indicates that the polyclonal antibodies present in RI-002 support its ability to prevent infections in immune-compromised patients. ADMA’s analysis demonstrated that the Phase III trial met the primary endpoint with no serious bacterial infections (SBI) reported. These results more than meet the requirement specified by the FDA guidance of ≤ 1 SBI per patient-year. A BLA was submitted to the FDA on July 31, 2015.

About ADMA Biologics, Inc.

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of PI and certain infectious diseases. ADMA’s mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, for which a notice of allowance for a U.S. patent was granted pertaining to RI-002 entitled “Compositions and Methods for the Treatment of Immunodeficiency,” has completed a Phase III clinical trial in patients with primary immune deficiency disease (PIDD) and has met the primary endpoint. A BLA for RI-002 was submitted to the FDA on July 31, 2015. For more information, please visit the company’s website at www.admabiologics.com.

About Primary Immune Deficiency Disease (PI)

PIDD is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly. PIDD patients are more vulnerable to infections and more likely to suffer complications from these infections. According to the World Health Organization, there are over 150 different presentations of PIDD. As patients suffering from PIDD lack a properly functioning immune system, they typically receive monthly, outpatient infusions of IGIV therapy. Without this exogenous antibody immune support, these patients would be susceptible to a wide variety of infectious diseases. PIDD has an estimated prevalence of 1:1,200 in the United States, or approximately 250,000 people.

Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “is likely”, “should,” “could,” “would,” “may” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning interpretations of final data, possible characteristics of RI-002, acceptability of RI-002 for any purpose by physicians patients or payers,  concurrence by FDA with our conclusions and the satisfaction by us of its guidance, the acceptability by the FDA of the BLA, the likelihood and timing of FDA action with respect to any further filings by the Company, results of the clinical development, continuing demonstrations of safety, comparability of results of RI-002 to other comparably run IVIG trials, improvements in clinical outcomes, potential of RI-002 to provide meaningful clinical improvement for patients living with PI, as well as to offer clinicians with an option for their immune compromised patients, market data and incidence of infection, regulatory processes, potential clinical trial initiations, potential investigational new product applications, biologics license applications, expansion plans, the achievement of clinical and regulatory milestones, commercialization efforts of the Company’s product candidate(s) and trends relating to demand for source plasma. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks as to whether final and secondary data will be accepted as encouraging, positive or will otherwise lead to an effective or approved product, whether we will be able to demonstrate efficacy or gain necessary approvals to market and commercialize any product, whether the FDA will accept our data, accept our submission of the BLA, continue to recognize its previously reported guidance, grant a license, or approve RI-002 for marketing, whether we will meet any of our clinical or regulatory milestones, whether we will develop any new products or expand existing ones, whether we will receive FDA approval of our new facility, whether there may be changes in regional and worldwide supply and demand for source plasma, whether we will be able to attract sufficient donors and operate our new facility effectively or profitably, whether we can sell our plasma in the marketplace at prices that will lead to adequate amounts of revenue, whether we will be able to sustain the listing of our common stock on the NASDAQ Capital Market, whether we will meet any timing targets expressed by the Company, and other risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent to the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

CONTACT: Brian Lenz
         Vice President and Chief Financial Officer
         201-478-5552 | www.admabiologics.com

(OCAT) to Host Conference Call and Webcast

Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, August 6, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the second quarter of 2015.

Interested parties may access the call live by dialing (888) 312-3054 (US) or (719) 325-2449 (international) and using conference ID 2737702.

A live audio webcast of the presentation will be available via the “Investor Relations” page of the Ocata website, www.ocata.com. A replay of the webcast will be archived on Ocata’s website for 90 days.

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.

About Age-related Macular Degeneration

Age-related macular degeneration is the leading cause of vision loss in people over the age of 50. Every year in the USA there are 1.8 million patients newly diagnosed with dry AMD which occurs when light-sensitive photoreceptor cells in the macula, located in the center of the retina, slowly break down, causing vision loss as a result. Photoreceptor breakdown is a consequence of loss or damage to the RPE layer. As the disease progresses, patients may have difficulty reading and recognizing faces. There is currently no proven medical therapy for dry AMD and the projected number of people worldwide with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040 underscoring the urgent need for new treatments.

About Stargardt’s Disease

Stargardt’s macular degeneration is a form of juvenile macular degeneration that affects vision in children and young adults between the ages of six and 20, with a prevalence of approximately one in 10,000 people in the United States. It is an orphan disease and loss of vision is an inevitable aspect of SMD, with more than half of the patients experiencing vision loss in the range of 20/200-20/400. Like dry AMD, it occurs as a result of damage to the RPE layer and there are no treatments currently approved to prevent or slow the vision loss associated with SMD.

Ocata Therapeutics, Inc.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com

(WWWW) Invites Small Businesses in the Greater Reno, NV Area to Seminar

The Web.com Small Business Summit to be Held in Conjunction With the PGA TOUR Barracuda Championship

JACKSONVILLE, Fla., July 31, 2015  — Web.com (Nasdaq:WWWW), a leading provider of Internet services and online marketing solutions for small businesses, will host a free Web.com Small Business Summit designed to help small business owners in the greater Reno, NV area learn how to successfully increase their business’ visibility and better market themselves online. The Web.com Small Business Summit will take place on Friday, August 7, 2015, from 9:00 a.m. – 12:00 p.m. at the Montreux Golf and Country Club in Reno, NV. Through Web.com’s agreement with the PGA TOUR and as umbrella sponsor of the Web.com Tour, Web.com developed the Small Business Summit as a benefit to small business owners in communities across the country.

“Entrepreneurs and small businesses continue to help the greater Reno area grow its job base and strengthen its overall economy,” said Chris Hoff, tournament director for the Barracuda Championship. “Small business owners have many competing demands on their time, foremost of which is running a business, and they don’t always have the knowledge to successfully market their business online. So with the help of our PGA TOUR partner, Web.com, we are pleased to help local small business owners continue to prosper and grow while also having the chance to enjoy the Barracuda Championship experience.”

Justin Leedy, director of Marketing at Web.com, will lead the discussion at the Web.com Small Business Summit on how small businesses can increase their online visibility and optimize their online marketing efforts. Danny Milrad, Product Marketing Director at Barracuda Networks will share best practices for securing and protecting applications and data while simplifying IT for small businesses.

Topics and content at the Web.com Small Business Summit focus on ways small business owners can achieve a successful Internet presence, including the elements of a great website, how to determine if their website is working for them, increasing traffic to their website and business, mobile marketing, and decoding how to efficiently market their business on Google, Facebook and Twitter.

“As part of our commitment to give back to the communities we serve, we are pleased to offer this event which is focused on helping small business owners improve their business model,” said Leedy. “Every day, Web.com helps millions of business owners address the challenges of building and maintaining an effective online presence that allows their businesses to grow. We expect a lively dialogue covering a range of key, timely topics that small business owners face when tackling this increasingly important digital opportunity.”

“It’s an exciting time in Reno-Tahoe with the second annual Barracuda Championship and the corresponding activities all week,” said Milrad. “The Web.com Small Business Summit is great addition to the line-up, offering customers an opportunity to learn more about better running their businesses and keeping their data safe online, all while participating in an impressive PGA TOUR event.”

Event Details:

• Where: Montreux Golf and Country Club, 18077 Bordeaux Drive, Reno, NV
• When: Friday, August 7, 2015, registration, refreshments and networking 9:00 a.m.; presentation will start promptly at 10:00 a.m. and will conclude by 12:00 p.m.
• Cost: Attendance is free, but advanced registration is requested at smallbusinesssummit.web.com
• Social media: Twitter: @webdotcom / Facebook: Web.com / Hashtag: #SmallBizSummit
• All attendees will receive a complimentary ticket to Barracuda Championship

For the schedule of all 2015 Web.com Small Business Summits or for more information about this Small Business Summit, go to the Web.com Small Business Summit website, or contact smallbusinesssummit@web.com, or call 800-862-8718.

Attention Editors/News Directors: Click here to view a brief video on what it’s like to attend a Web.com Small Business Summit event.

About Web.com

Web.com Group, Inc. (Nasdaq:WWWW) provides a full range of Internet services to small businesses to help them compete and succeed online. Web.com is owner of several global domain registrars and further meets the needs of small businesses anywhere along their lifecycle with affordable, subscription-based solutions including website design and management, search engine optimization, online marketing campaigns, local sales leads, social media, mobile products, eCommerce solutions and call center services. To get more information, visit www.web.com; follow Web.com on Twitter @webdotcom or on Facebook at Facebook: Web.com. For additional online marketing resources and small business networking, please visit Web.com’s Small Business Summit.

About PGA TOUR

The PGA TOUR is the world’s premier membership organization for touring professional golfers, co-sanctioning more than 130 tournaments on the PGA TOUR, Champions Tour, Web.com Tour, PGA TOUR Latinoamérica, PGA TOUR Canada and PGA TOUR China.

The PGA TOUR’s mission is to entertain and inspire its fans, deliver substantial value to its partners, create outlets for volunteers to give back, generate significant charitable and economic impact in the communities in which it plays, and provide financial opportunities for TOUR players.

Worldwide, PGA TOUR tournaments are broadcast to more than 1 billion households in 225 countries and territories in 32 languages. Virtually all tournaments are organized as non-profit organizations in order to maximize charitable giving. In 2013, tournaments across all Tours generated more than $134 million for local and national charitable organizations and in early 2014 the TOUR’s all-time charitable contributions surpassed $2 billion.

The PGA TOUR’s web site is PGATOUR.COM, the No. 1 site in golf, and the organization is headquartered in Ponte Vedra Beach, Fla.

Note to Editors: Web.com is a registered trademark of Web.com Group, Inc.

CONTACT: Media Contact:
         Ashley Clontz
         Golin for Web.com
         972-701-6974
         aclontz@golin.com

(PLUG) Completes Acquisition of HyPulsion Joint Venture in Europe

Plug Power Now Poised to Convert $20 Billion European Electric Lift Truck Market to Hydrogen Fuel Cells

LATHAM, N.Y., July 31, 2015  — Plug Power Inc. (NASDAQ:PLUG), a leader in providing clean, reliable energy solutions, announced it has completed the previously announced acquisition of HyPulsion, the European joint venture created by Plug Power and Axane, S.A., a subsidiary of Air Liquide S.A. in 2012. Effective immediately, Plug Power will assume all responsibilities for the development, engineering, sales and marketing efforts in Europe for its GenFuel hydrogen and GenDrive fuel cell product lines and corresponding GenCare services.

Plug Power will offer its CE-certified GenDrive products to European lift truck customers in the $20 billion European electric lift truck market. For the short-term, Plug Power will continue to develop, engineer, and manufacture all products in the United States with a sales and service force in Europe.

Air Liquide will remain a strategic hydrogen production partner to Plug Power, acting as a hydrogen supplier to Plug Power’s material handling customers. Additionally, Air Liquide will continue to represent a seat on Plug Power’s board of directors, a position held since 2012.

“Plug Power is ready to move in Europe,” said Andy Marsh, CEO of Plug Power. “Our success with customers like BMW and Volkswagen has helped open doors in Europe, a $20 billion market where customers have a strong mandate for cleaner, more productive distribution centers and where Plug Power has an impressive head start on our competitors.”

About Plug Power Inc.

The powerhouse in hydrogen fuel cell technology, Plug Power is revolutionizing the industry with cost-effective solutions that increase productivity, lower operating costs and reduce carbon footprint. Its signature solution, GenKey, provides an all-inclusive package for customers, incorporating GenFuel hydrogen and fueling infrastructure, GenCare aftermarket service and either GenDrive or ReliOn fuel cell systems. GenDrive, a lead-acid battery replacement, is used in electric lift trucks in high-throughput material handling applications. With more than 7,000 GenDrive units deployed with material handling customers, GenDrive has been proven reliable with over 100 million hours of runtime. Plug Power manufactures tomorrow’s incumbent power solutions today, so customers can POWERAhead. Additional information about the Plug Power brands is available at www.plugpower.com.

Plug Power Inc. Safe Harbor Statement

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (“PLUG”), including but not limited to statements about expansion into and growth in the European hydrogen and fuel cell market. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, the risk that we continue to incur losses and might never achieve or maintain profitability; the risk that we will need to raise additional capital to fund our operations and such capital may not be available to us; the risk that our lack of extensive experience in manufacturing and marketing products may impact our ability to manufacture and market products on a profitable and large-scale commercial basis; the risk that unit orders will not ship, be installed and/or converted to revenue, in whole or in part; the risk that pending orders may not convert to purchase orders, in whole or in part; the risk that a loss of one or more of our major customers could result in a material adverse effect on our financial condition; the risk that a sale of a significant number of shares of stock could depress the market price of our common stock; the risk that negative publicity related to our business or stock could result in a negative impact on our stock value and profitability; the risk of potential losses related to any product liability claims or contract disputes; the risk of loss related to an inability to maintain an effective system of internal controls or key personnel; the risks related to use of flammable fuels in our products; the cost and timing of developing, marketing and selling our products and our ability to raise the necessary capital to fund such costs; the ability to achieve the forecasted gross margin on the sale of our products; the risk that our actual net cash used for operating expenses may exceed the projected net cash for operating expenses; the cost and availability of fuel and fueling infrastructures for our products; market acceptance of our products, including GenDrive, ReliOn and GenKey systems; the volatility of our stock price; our ability to establish and maintain relationships with third parties with respect to product development, manufacturing, distribution and servicing and the supply of key product components; the cost and availability of components and parts for our products; our ability to develop commercially viable products; our ability to reduce product and manufacturing costs; our ability to successfully expand our product lines; our ability to successfully expand internationally; our ability to improve system reliability for our GenDrive, ReliOn and GenKey systems; competitive factors, such as price competition and competition from other traditional and alternative energy companies; our ability to protect our intellectual property; the cost of complying with current and future federal, state and international governmental regulations; risks associated with potential future acquisitions; and other risks and uncertainties referenced in our public filings with the Securities and Exchange Commission. For additional disclosure regarding these and other risks faced by PLUG, see disclosures contained in PLUG’s public filings with the Securities and Exchange Commission (the “SEC”) including, the “Risk Factors” section of PLUG’s Annual Report on Form 10-K for the year ended December 31, 2014. You should consider these factors in evaluating the forward-looking statements included in this presentation and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information.

CONTACT: Plug Power Media Contact
         Teal Vivacqua
         518.738.0269
         media@plugpower.com

(SMTP) Rick Carlson Appointed President

SMTP Taps Carlson to Take on Broader Role in Organization

NASHUA, N.H., July 31, 2015  — SMTP, Inc. (NASDAQ:SMTP), a global provider of cloud-based marketing technologies, announced today that Rick Carlson, President of SharpSpring, will be appointed President of SMTP, Inc. effective August 1, 2015, reflecting a broader role across the organization. In this new role, Rick will continue to drive SharpSpring’s growth but will also have responsibilities over marketing, product and operations across the entire company.

“Rick is a proven leader who has the experience and track record of delivering results,” said Jon Strimling, SMTP’s CEO. “His product vision and leadership drove SharpSpring to rapidly become a leading player in the fast growing marketing automation technology space. We are confident that Rick will help lead SMTP to new levels in the years to come.”

Carlson joined SMTP in the August 2014 acquisition of SharpSpring, and has quickly gained the respect and admiration of the company’s team worldwide. His results-oriented approach and focus on accountability have been instrumental in SharpSpring’s rapid adoption as a marketing automation provider.

“I am honored to serve as the President of SMTP,” said Rick Carlson. “Since joining the company last year, I have had the pleasure of working with a fantastic team of managers and leaders.   I am excited to expand my work with Jon, the technology and management teams, and the great people across our organization.  Together, we intend to continue to transform SMTP into a market leader, drive growth and create value for shareholders, across all of our products and services.”

About SMTP, Inc.

SMTP, Inc. (NASDAQ:SMTP) is a global provider of cloud-based marketing solutions ranging from sophisticated marketing automation (via subsidiary SharpSpring) to comprehensive email and mobile marketing (via subsidiary GraphicMail) and scalable, cost-effective email deliverability services. The company’s product family is hallmarked by its flexible architecture, ease-of-use and cost-effectiveness. SMTP augments its technology with high-quality, multilingual customer service and support. SMTP, Inc. is headquartered in Nashua NH, and can be found on the web at www.smtp.com. SharpSpring, based in Gainesville, FL, can be found on the web at www.SharpSpring.com. GraphicMail, based in Geneva, Switzerland, can be found on the web at www.GraphicMail.com.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continues,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing new customer offerings, changes in customer order patterns, changes in customer offering mix, continued success in technological advances and delivering technological innovations, delays due to issues with outsourced service providers, those events and factors described by us in Item 1.A “Risk Factors” in our most recent Form 10-K and other risks to which our Company is subject, and various other factors beyond the Company’s control.

CONTACT: Investor Relations Contact:
         Edward Lawton
         Chief Financial Officer
         (617) 500-0122
         ir@smtp.com

(GUID) to Highlight Inside-Out Security Framework at Black Hat USA

Guidance Software, Inc. (NASDAQ: GUID), makers of EnCase®, the gold standard for digital investigations and endpoint data security, today announced the publication of its vendor-agnostic Inside-Out Security Framework and will discuss it at Black Hat USA 2015. Researchers will demonstrate how taking an Inside-Out approach to information security enables active defense to combat today’s advanced threats, such as the proliferation of remote access terminal (RAT) malware types like those seen in recent commercial and government data breaches.

“Security teams are grappling with the complex challenge of spotting custom or zero-day malware variants that have been instrumental in some of the most widely publicized cyber attacks,” said Scott Crawford, Research Director of the Information Security practice at 451 Research. “The Inside-Out Security Framework offers an actionable example of a process that illuminates the critical blind spots of traditional, perimeter-focused approaches.”

The Inside-Out Security Framework breaks the security planning process into four phases:

1. Know Yourself: Create a security plan, build a baseline, identify your blind spots, and close the gaps.
2. Detect: Detect known threats, then detect unknown threats.
3. Respond: Automate response, enable remote investigation, analyze malware, and determine scope.
4. Recover: Remediate, verify and update, enrich data, and repeat.

“Knowing yourself” involves gaining visibility to all the places where sensitive data is stored on network endpoints. Security teams that do this are better equipped to respond quickly when anomalous activity is taking place there. For example, the ability to spot an unauthorized or unusual connection to a remote IP address can serve as a trigger for a team to search for unusual activity and indicators of compromise on the endpoint in question, including the forensic artifacts that RAT malware cannot avoid leaving behind.

“Our vision is to help companies and government agencies spot unknown threats earlier in order to prevent data breaches. Inside-out security approaches put the focus on knowing your endpoints and protecting the information assets that reside there,” said Roger Angarita, Director of Product Management at Guidance Software. “Our research confirms the message in headline news: perimeter-focused security approaches aren’t keeping determined hackers out of our networks. It’s time for security teams to take an inside-out security approach using deep and rapid endpoint intelligence from inside the firewall.”

Guidance Software will be presenting the Inside-Out Security Framework and a demonstration of RAT malware capture at Black Hat USA 2015. For more information on the Inside-Out Security Framework or to see a demonstration of the RAT-hunting process, visit booth #641 in the Black Hat Business Hall on August 5-6, 2015.

About Guidance Software

Guidance Software, Inc. (NASDAQ: GUID), the maker of the EnCase technology platform, is the gold standard in digital investigations and endpoint data security, helping organizations around the world lower business risk by providing the most complete visibility to data everywhere it’s stored—on the endpoint, across servers, and into the cloud. Guidance Software solutions are built for integration within a rich technology ecosystem, including Dropbox, HP, Cisco, Box, and Blue Coat Systems, and widely adopted within multiple industries where compliance is critical, such as financial, insurance, defense, energy, pharmaceutical, manufacturing, and retail. Recognized as the market leader in endpoint detection and response by Gartner, the company’s EnCase platform has been deployed on an estimated 25 million endpoints and is used with confidence by more than 70 of the Fortune 100 and hundreds of government agencies around the world.

For more information about Guidance Software, please visit www.guidancesoftware.com, “Like” our Facebook page, follow us on Twitter, or follow our LinkedIn page.

EnCase®, EnScript®, FastBloc®, EnCE®, EnCEP®, Guidance Software™, LinkedReview™, EnPoint™ and Tableau™ are registered trademarks or trademarks owned by Guidance Software in the United States and other jurisdictions and may not be used without prior written permission. All other trademarks and copyrights referenced in this press release are the property of their respective owners.

GUID-F

(MGI) Announces Leadership Succession Plan

W. Alexander Holmes to Become Chief Executive Officer January 1, 2016 Pamela H. Patsley to Serve as Executive Chairman Through 2017

DALLAS, July 31, 2015  — MoneyGram (NASDAQ: MGI), a leading global money transfer and payment services company, announced today that its Board of Directors has chosen W. Alexander Holmes to serve as MoneyGram’s next chief executive officer, beginning on January 1, 2016. He will succeed MoneyGram chairman and CEO Pamela H. Patsley, who on the same date will assume the role of executive chairman for a minimum of two years. Holmes, currently the Company’s executive vice president, chief financial officer and chief operating officer, will join the MoneyGram Board by the start of his tenure as CEO.

(EVAR) Acquires Endovascular Stent Graft Developer Altura Medical

Acquisition Expands Lombard Product Portfolio with Simple, Safe and Efficient Ultra-Low Profile Endovascular Stent Graft

CE Mark in Place – European Launch Scheduled for January

IRVINE, Calif., July 30, 2015  — Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that has developed an innovative ultra-low profile endovascular stent graft technology that offers a simple and predictable solution for the treatment of standard AAA anatomies.

The terms of the transaction include the issuance of $15 million of Lombard common stock at $4 per share (3,750,000 shares of Lombard common stock subject to certain lock up conditions), the assumption of $5.5 million in bank debt and $2.5 million in certain liabilities and transaction-related costs.

In addition, up to $27.5 million may be paid based on the achievement of certain commercial and regulatory milestones anticipated over the next five years. Under the terms of the agreement, Lombard has the option to pay the additional consideration in either cash or stock.

The Altura endograft system received CE Mark in 2015 and Lombard plans to launch the device in Europe in January 2016 with a broader international roll out later the same year. In the U.S., Lombard intends to file for an IDE (Investigational Device Exemption) from the U.S. FDA in early 2016 with the intent to begin recruitment for a U.S. clinical study later in 2016.

Lombard CEO Simon Hubbert said, “The acquisition of Altura and the launch of its new AAA stent graft will provide a near-term and substantial increase in revenues. In fact, we believe this innovative technology could account for up to 20 percent of our 2016 total revenue. The combination of Altura’s technology with our flagship Aorfix™ platform creates a truly patient driven platform that we believe will allow us to capture share from our competitors. The Altura device offers a simple, safe and efficient treatment option for standard AAA anatomy, while Aorfix offers the only on-label solution for patients with Aortic neck angulation up to 90 degrees.”

“The Altura device offers a new ultra-low profile stent graft system without compromising the robustness and durability of the wire and graft fabric,” said Professor Dierk Scheinert, M.D., Chairman of the Division of Interventional Angiology, University Hospital Leipzig, Germany. Noting that, “The added benefits of this smart system are the ability to reposition during deployment and place each graft accurately to each renal artery enabling physicians to utilize all the available aortic neck. It also removes the need for cannulation and therefore provides a simple, intuitive, safe and consistent deployment system with predictable and shorter procedure times.”

“Many patients who present for AAA repair can be treated quickly and efficiently with minimal hospital stay and recovery times,” said Stuart A. Harlin, M.D., board certified vascular surgeon, Coastal Vascular & Interventional, Pensacola, FL. “The introduction of an easy-to-deploy AAA stent graft that offers enhanced safety and accuracy on an ultra-low profile delivery system will allow physicians to treat a large percentage of AAA patients more efficiently in the future.”

Conference Call

Lombard’s management will discuss the acquisition and answer questions during a conference call, which will include a slide presentation, beginning at 5:00 p.m. Eastern Time today, Thursday, July 30, 2015. To join the call, participants may dial 1-855-327-6837 (domestic), 0808-101-2791 (UK toll-free) or 1-631-982-4565 (international). To access the slide presentation and/or listen to a live webcast of the conference call, visit the Events and Presentations page under the Investors tab at www.lombardmedical.com. Phone participants who are accessing the slides from the webcast link should, after completing the registration, click the “Listen by Phone” black box under the smaller screen on the left hand side to turn off the webcast audio and sync the slides to the phone audio.

An archived replay of the webcast will be available shortly following the completion of the call on the Events and Presentations page under the Investors tab at www.lombardmedical.com.

About Altura Medical, Inc.

Founded in 2008 and based in Menlo Park, CA, Altura Medical has developed a next generation endograft technology to treat AAA and other related conditions. The development of Altura’s highly differentiated technology was led by experienced technologists and supported by a prestigious syndicate of venture capital investors, including SV Life Sciences, New Leaf Ventures and Advanced Technology Ventures. Andrew Cragg, MD, a prolific physician inventor, entrepreneur and a principal at Intersect Partners, initially conceived the Altura AAA endograft technology.

About Lombard Medical, Inc.

Lombard Medical, Inc. is an Irvine, CA-based medical device company focused on device solutions for the $1.6 billion per year abdominal aortic aneurysm repair market. The Company’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomies, which are often present in advanced AAA disease. Aorfix has been used to treat more than 4,000 patients worldwide. The Company’s lead product, Aorfix™, is the only endovascular stent graft cleared by the U.S. Food and Drug Administration (FDA) for the treatment of AAAs with angulation at the neck of the aneurysm of up to 90 degrees providing physicians in the U.S. with the only ‘on-label’ endovascular treatment option for patients with this complex AAA anatomy. All other approved grafts are only cleared by the FDA for the treatment of neck angulation up to 60 degrees. For more information, please visit www.lombardmedical.com.

Forward-Looking Statements

This announcement contains forward-looking statements that reflect the Company’s current expectations regarding future events. These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “expect,” “future,” “anticipate,” “look forward to,” “intend,” “plan,” “foresee,” “may,” “should,” “will,” “estimates,” “outlook,” “potential,” “optimistic,” “confidence,” “continue,” “evolve,” “expand,” “growth” or words and phrases of similar meaning. Statements that describe objectives, plans or goals also are forward-looking statements. Forward-looking statements are subject to risks, management assumptions and uncertainties. Actual results could differ materially from those projected herein and depend on a number of factors, including the success of the Company’s research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company’s products by hospitals and other medical professionals, the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company’s products and increased volatility in foreign exchange rates, the inability to raise additional funds, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s Form 20-F filed with the Securities and Exchange Commission dated April 29, 2015.  Readers are urged to consider these factors carefully in evaluating the forward-looking statements. The forward-looking statements included herein are made only as of the date of this report and the Company undertakes no obligation to update these statements in the future.

For further information:

(MXWL) Selected as Exclusive CE Storage Supplier by China’s Largest Rail Company

China Qingdao Sifang Rolling Stock Research Institute and Maxwell Sign Multi-year Strategic Agreement

SAN DIEGO, July 30, 2015  — Maxwell Technologies, Inc. (Nasdaq: MXWL), a leading developer and manufacturer of ultracapacitor-based energy storage solutions, announced today that it has signed a long-term strategic partnership agreement with China Railway Rolling Stock Corporation (CRRC-SRI, formerly CNR-SRI), subsidiary of CRRC, one of the largest rail vehicle manufacturers in the world. The agreement will examine multi-year collaboration activities between the two companies to jointly develop new application-specific, next-generation capacitive energy storage solutions that meet the unique application requirements of CRRC-SRI’s customers in the Chinese rail market.

Capacitive energy storage technology offers high-power density performance under extreme temperatures with long operational lifetimes and is ideally suited for rail transportation applications, particularly onboard commuter rolling stock modalities such as subway and light rail. CRRC-SRI selected Maxwell based on its global leadership in developing and delivering high-quality ultracapacitor solutions proven in global transportation applications such as start-stop autos and hybrid buses, which require rapid braking, energy recuperation and power delivery. Maxwell will work closely with CRRC-SRI to develop solutions uniquely designed to address the growing Chinese rail market.

“The current expansion of rail transportation infrastructure in China will continue well into the next decade and has higher requirements on energy saving and environment protection now and in the future, particularly for onboard rail vehicles,” said Liu Baoming, chairman of CRRC-SRI. “We firmly believe capacitive energy storage technology is essential to providing solutions that meet those energy-saving and environment-protection requirements. We highly value Maxwell Technologies’ expertise in capacitive energy storage and trust its technology leadership to help us keep pace with the rate of innovation required now and into the next decade.”

“Rail transportation applications are an excellent match for ultracapacitors, and the rail market will be a significant opportunity for Maxwell,” said Dr. Franz Fink, Maxwell’s president and chief executive officer. “In China, advanced energy storage and power delivery solutions will play an increasingly important role in improving efficiencies and reducing carbon emissions. Our partnership with CRRC-SRI represents an excellent opportunity for us to generate meaningful revenue in a three-to-five-year horizon through the co-development of application-specific technology and products for the expanding China rail market.”

Additional Maxwell Technologies information:

• Maxwell Technologies on Twitter: https://twitter.com/Maxwell_Tech
• Maxwell Technologies on Facebook: http://on.fb.me/10e2nPA
• Maxwell Technologies on LinkedIn: http://linkd.in/Z4737Y
• Maxwell Technologies on Google+: https://plus.google.com/+MaxwellTech/
• More information about ultracapacitors: http://www.maxwell.com/ultracapacitors

About Maxwell Technologies: Maxwell Technologies is a global leader in the development and manufacture of innovative, cost-effective energy storage and power delivery solutions. Our ultracapacitor products provide safe and reliable power solutions for applications in consumer and industrial electronics, transportation and telecommunications. Our high-voltage grading and coupling capacitors help to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution and measurement of high-voltage electrical energy. Our radiation-mitigated microelectronic products include power modules, memory modules and single board computers that incorporate powerful commercial silicon for superior performance and high reliability in aerospace applications. For more information, please visit our website: www.maxwell.com.

Maxwell Technologies Contacts:

Media: Sylvie Tse, Metis Communications: +1 (617) 236-0500; maxwell@metiscomm.com
Investor: Michael Sund: +1 (858) 503-3233; msund@maxwell.com

(HTCH) Introduces New Gemini SMA OIS Actuator

New Design Can Enable the World’s Slimmest OIS Smartphone Cameras

HUTCHINSON, Minn., July 30, 2015  — Hutchinson Technology Incorporated (NASDAQ:HTCH) today announced that it expects to begin shipping prototypes of a new Shape Memory Alloy Optical Image Stabilization (SMA OIS) actuator to tier 1 camera module manufacturers in early August. The new Gemini product was designed in response to customer requests for reduced OIS camera thickness. Gemini reduces SMA OIS actuator thickness by more than 70%, to enable the world’s slimmest OIS smartphone cameras.

Gemini also improves handshake suppression, resulting in clearer photos in low light conditions and more stabilized videos. The unique properties of shape memory alloy wire enable a more compact, higher force, and a more rugged actuator than industry standard voice coil motor designs.

The Gemini design significantly lowers the company’s capital and manufacturing costs by reducing the number of components in the product and better leveraging the company’s existing production equipment. “Our proven automated processes, quality control systems, and high volume precision manufacturing capabilities position us well to support large smartphone programs,” said Rick Penn, Hutchinson Technology’s president and chief executive officer.

Building on the value users place on “selfie” photos, Hutchinson Technology is also developing SMA OIS designs to improve front-facing camera image quality. With superior miniaturization capabilities, SMA OIS is an excellent candidate for spatially constrained front-facing cameras. Unlike voice coil motor actuators, SMA OIS actuators do not use magnets. This eliminates magnetic interference that could occur due to the camera’s close proximity to the phone’s antenna.

SMA OIS products offer a unique blend of smallest size, excellent performance, and industry leading shock reliability. Gemini is expected to be ready for volume production in CQ4 2015. Front-facing SMA OIS samples are also expected to be available in CQ4.

More information about Gemini OIS actuators can be found on Hutchinson Technology’s website at http://www.htchmfg.com/gemini-sma-ois.html.

About Hutchinson Technology

Hutchinson Technology is a global supplier of critical precision component technologies. As a key supplier of suspension assemblies for disk drives, we help customers improve overall disk drive performance and meet the demands of an ever-expanding digital universe. Through our new business development initiatives, we focus on leveraging our unique precision manufacturing capabilities in new markets to improve product performance, reduce size, lower cost, and reduce time to market.

Cautionary Note Regarding Forward-Looking Statements

This announcement contains forward-looking statements regarding development, market adoption and production of OIS actuators and product performance.  The company does not undertake to update its forward-looking statements.  These statements involve risks and uncertainties.  The company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of changes in market demand and market consumption of smartphones, changes in demand for our products, market acceptance of new products, the company’s ability to produce SMA OIS actuators at levels of precision, quality, volume and cost its customers require and other factors described from time to time in the company’s reports filed with the Securities and Exchange Commission.

CONTACT: MARKETING CONTACT:
         Keith Johnson
         Hutchinson Technology Inc.
         320-587-1203

         INVESTOR CONTACT:
         Chuck Ives
         Hutchinson Technology Inc.
         320-587-1605

(GEVO) First Pump Sales of Isobutanol-Blended Gasoline at Express Lubes in Texas

Sales Focused at Owners of Boats, Outdoor Equipment and Off-Road Vehicles

ENGLEWOOD, Colo., July 30, 2015  — Gevo, Inc. (NASDAQ:GEVO), has announced that Express Lube of Fredericksburg, Texas, is the first U.S. service station to sell gasoline blended with Gevo’s renewable isobutanol at the pump. This is anticipated to be the first of many retail locations to offer Gevo’s product as the company rolls out its isobutanol to the marina, outdoor equipment and off-road gasoline markets.

According to Express Lube owner Adam Sheffield, he decided to sell isobutanol-blended gasoline because its moisture resistance and capacity to reduce engine corrosion are ideal for equipment and vehicles that are used intermittently. Sheffield learned about Gevo’s renewable isobutanol from Kino Oil, a local distributor that sells the product in drums. Kino began to offer the fuel made with isobutanol after finding that it is ethanol-free and is excellent for use with marine and off-road engines.

As a result of this improved performance provided by isobutanol-blended gasoline, Express Lube has been selling its fuel at over a 50 percent premium in comparison to local E10 gasoline blends (10 percent ethanol).

Gevo’s isobutanol is blended with gasoline to help meet renewable fuel and clean air standards, and after several years of work and testing, has successfully obtained registration with the U.S. EPA as a fuel additive. Recently, the National Marine Manufacturers Association officially endorsed isobutanol as a drop-in fuel for marine and recreational boat engines. Gevo believes that retail sales of isobutanol-blended gasoline by Express Lube will help establish the value proposition for other fuel retailers.

“Isobutanol is great for weed eaters, mowers and farm or ranch equipment that sits unused for long periods of time – because it does not cause carburetors to gum up the way ethanol does,” says Sheffield. “I tried it myself after discovering that the ethanol-blended gasoline sitting in my riding mower over the winter had ruined the carburetor. It cost me $700 to replace. That’s when I switched to isobutanol.”

“We welcome Express Lube as the very first retail service station to sell gasoline made with our isobutanol. It’s only a matter of time before other distributors and gas stations across the U.S. and in other parts of the world discover the benefits of isobutanol, and begin to offer our product commercially as well,” said Dr. Patrick Gruber, Chief Executive Officer of Gevo.

About Gevo

Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo’s strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, MN. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, TX, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo has a marquee list of partners including The Coca-Cola Company, Toray Industries Inc. and Total SA, among others. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water.

About Express Lube

The Express Lube service station in Fredericksburg, Texas, near Hill Country, is dedicated to providing the highest quality oil and fuel products available. This includes products for cars, trucks, ATVs, lawn care, farm & ranch equipment, chain saws, gas generators, marine and recreational boats, and racing vehicles.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2014, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Gevo. Certain statements in this press release are based on publicly available published studies conducted by the National Marine Manufacturers Association, marine engine manufacturers, the United States Coast Guard, national laboratories, the United States Department of Energy and others.

CONTACT: Media Contact
         Karen Freedman / David Rodewald
         The David James Agency, LLC
         +1 805-494-9508
         gevo@davidjamesagency.com

         Investor Contact
         Mike Willis
         Gevo, Inc.
         +1 720-267-8636
         mwillis@gevo.com

(LPSN) to Present at Oppenheimer 18th Annual Conference

NEW YORK, July 30, 2015  — LivePerson, Inc. (Nasdaq: LPSN), a leading provider of digital engagement solutions, today announced that the Company will be presenting at the Oppenheimer 18th Annual Technology, Internet & Communications Conference in Boston at 11:45 a.m. ET on Tuesday, August 11, 2015. A copy of the presentation will be accessible through the Investors section of the company’s web site, www.liveperson.com.

About LivePerson, Inc.

LivePerson, Inc. (Nasdaq: LPSN) offers a cloud-based platform that enables businesses to proactively connect in real-time with their customers via chat, voice, and content delivery at the right time, through the right channel, including websites, social media, and mobile devices. This “intelligent engagement” is driven by real-time behavioral analytics, producing connections based on a true understanding of business objectives and customer needs. For more information, please visit www.liveperson.com. To view other global press releases about LivePerson, please visit pr.liveperson.com.

Investor Relations Contact
Matthew Kempler
mkempler@liveperson.com
212-609-4214

(QUIK) Announces the EOS Platform, the World’s Most Advanced Sensor Processing SoC

(IMNP) Secures Funding Of Up To $21.5 Million From Institutional Investors

Up to $9.5 Million in Debt Financing and $12 Million in Equity Financing Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product Candidates Lead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority

NEW YORK, July 29, 2015  — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has secured financings of up to $21.5 million through two financing agreements. The first, with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules”), for a term loan of up to $9.5 million. The second agreement, with mutual fund Discover Growth Fund (“Discover”), for the sale to Discover of newly created Series D Redeemable Convertible Preferred Stock (“Preferred Stock”) for up to $12 million in gross proceeds to the company.

Immune received $13.5 million in gross proceeds: $9.0 million from Discover and $4.5 million from Hercules, following the execution of the two agreements.  Immune expects to receive an additional $3.0 million from Discover upon an effective “resale” registration statement for the securities sold and stockholders approval in accordance with the NASDAQ rules (stockholders of the company, representing close to 50% of the voting power as of July 28, 2015, have already agreed to vote in favor of such proposal).  Immune also has the option to draw down additional capital under the term loan with Hercules of up to $5.0 million prior to June 15, 2016, subject to certain clinical milestones and other conditions.

“We believe bertilimumab is a promising first-in-class clinical asset with the potential to address unmet medical needs for several inflammatory and auto-immune conditions,” said Himani Bhalla, Principal at Hercules.  “Hercules’ track record of investing in numerous biotechnology companies focused on antibody therapeutics provides us with an insight into the potential of the Immune pipeline,” she added.

The Preferred Stock issued to Discover is convertible at a fixed price of $2.50 per share and has a six and a half year maturity term, at which time it will convert automatically into common stock at $2.50 per share. The preferred stock bears an accrued annual dividend rate of 8.0%, which may range from 0% to 15%, based on certain adjustments and conditions.  The dividend is payable in cash or common stock at the sole discretion of Immune.

“These financing agreements offer a vote of confidence from two institutional investors, Hercules and Discover, in support of clinical development for our drug candidate, bertilimumab, in bullous pemphigoid and ulcerative colitis”, said Dr. Daniel Teper, Chief Executive Officer, Immune.  “With this financing, we intend to pursue a three-fold approach to advance our pipeline in addition to the two key indications described:  explore additional indications for bertilimumab, bring the topical nano-formulated cyclosporine program into clinical trials in atopic dermatitis and psoriasis, and advance our lead NanomAb candidate to Phase I in oncology,”

“This financing extends our working capital for the next eighteen to twenty four months. It strengthens our balance sheet in support of growth-oriented research and development activities consistent with our long-range business plan.  In addition, this financing strengthens our ability to maximize the value of the AmiKet™ asset in our on-going partnering discussions”, added Gad Berdugo, Executive Vice President and Chief Financial Officer of Immune.

Further information with respect to the definitive agreements with Hercules and Discover is contained in a Current Report on Form 8-K which will be filed by Immune Pharmaceuticals with the Securities and Exchange Commission.

Immune’s senior management will provide additional information on the financing, progress of its clinical trials and partnering activities, following the release of its second quarter financial report, in a conference call on Monday August 17^th, 2015.

Roth Capital Partners and Chardan Capital Markets acted as co-lead placement agents on the Discover transaction. TriPoint Global Equities acted as sole placement agent on the Hercules transaction.

444 shares of Preferred Stock described above, and the shares of common stock issuable upon conversion of the Preferred Stock and any dividends payable thereof, were offered by the company pursuant to a prospectus supplement to the company’s “shelf” registration statement on Form S-3 (File No. 333-198647), which became effective on October 28, 2014. 503 of the shares of Preferred Stock, and the shares of common stock issuable upon conversion of the Preferred Stock and any dividends payable thereof, have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), will be issued in the concurrent private placement pursuant to the exemption provided in Section 4(a)(2) under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.  The Preferred Stock was offered only to one institutional accredited investor.  Immune has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon conversion of the Preferred Stock issued in the private placement as well as any dividends payable in shares of common stock.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.  Immune has filed a prospectus supplement with the SEC relating to the shares of Preferred Stock, and the shares of common stock issuable upon conversion of the Preferred Stock and any dividends payable thereof, issued in the registered direct offering.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a topical neuropathic pain drug candidate.

For more information, visit Immune’s website at www.immunepharmaceuticals.com

About Hercules Technology Growth Capital, Inc.

Hercules Technology Growth Capital, Inc. (NYSE: HTGC) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related industries, including technology, biotechnology, life sciences, and energy and renewable technology, at all stages of development. Since inception (December 2003), Hercules has committed more than $5.2 billion to over 320 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.  Companies interested in learning more about financing opportunities should contact info@htgc.com, or call 650.289.3060.

About Discover Growth Fund

Discover Growth Fund is a mutual fund, focused on making equity investments into small-cap and micro-cap public companies that have substantial growth potential.  The Fund employs a fundamental equity investment strategy, which is characterized by intensive due diligence, first-hand research and disciplined company evaluation.  The portfolio is comprised of smaller capitalization companies that are higher quality, have more effective management, and superior business models likely to produce higher returns for our investors.  For more information on Discover Growth Fund visit www.dgfund.com.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal” or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

(GSOL) Announces Preliminary Tender Offer Results

NEW YORK, July 29, 2015  — Global Sources Ltd. (NASDAQ: GSOL) announced today the preliminary results of its cash tender offer to purchase up to 6,666,666 shares of its issued and outstanding common shares at a price of $7.50 per share. The offer to purchase shares commenced on June 26, 2015 and expired at 12:00 midnight, New York City time, on July 27, 2015.

As of July 27, 2015, the company’s shares closed at $6.61 per share, as compared to $6.81 per share as of June 26, 2015, the date the tender offer commenced.

Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the tender offer, approximately 12.6 million shares of the company’s common shares were properly tendered and not properly withdrawn. The number of shares properly tendered and not properly withdrawn is preliminary and subject to change. Given that the number of shares tendered was greater than the number of shares that the company offered to purchase, it will be necessary to apply the “odd lot” priority and pro-ration provisions described in the company’s offer to purchase. The “odd lot” priority and pro-ration process is estimated to be concluded by July 30, 2015 and payment to shareholders is expected to promptly commence after that process has been completed. The company will issue payment of $7.50 per share for all “odd lot” and pro-rata shares that were properly tendered and not properly withdrawn.

Based on the preliminary results of the tender offer, the company will become a “controlled company” under the NASDAQ rules upon the completion of the tender offer. As noted in the company’s offer to purchase, the company has no present intention to avail itself of the corporate governance exceptions afforded to a “controlled company” under the NASDAQ rules.

In addition to Computershare’s role as the depositary, Georgeson Inc. served as the information agent. Questions regarding the tender offer should be directed to Georgeson. All shareholders can contact Georgeson by calling them at: (1-888) 607-6511. Non-U.S. shareholders can contact Georgeson by calling them at: (1-781) 575-2137. Alternatively, shareholders can email Georgeson at globalsources@georgeson.com. These telephone numbers and email address are scheduled to remain operational until at least Aug. 26, 2015.

About Global Sources

Global Sources is a leading business-to-business media company and a primary facilitator of trade with Greater China.

The core business facilitates trade between Asia and the world using English-language media such as online marketplaces (GlobalSources.com), print and digital magazines, sourcing research reports, private sourcing events, and trade shows.

More than 1 million international buyers, including 95 of the world’s top 100 retailers, use these services to obtain product and company information to help them source more profitably from overseas supply markets. These services also provide suppliers with integrated marketing solutions to build corporate image, generate sales leads and win orders from buyers in more than 240 countries and territories.

Now in its fifth decade, Global Sources has been publicly listed on the NASDAQ since 2000.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27-A of the Securities Act of 1933, as amended and Section 21-E of the Securities Exchange Act of 1934, as amended. The company’s actual results could differ materially from those set forth in the forward-looking statements as a result of the risks associated with the company’s business, changes in general economic conditions, and changes in the assumptions used in making such forward-looking statements.

(UNIS) Introduces World’s First Instant Patch Pump for Insulin

Conference Call on Thursday, July 30 at 8:30 a.m. EDT*** Imperium™ combines therapeutic advantages of pumps with low cost and convenience of prefilled pens Enables Unilife and prospective insulin partners to penetrate large, growing Type 2 diabetes market

(TOR) to Attend Global Industrial Supply Chain Fellowship Meeting

CHANGSHU, China, July 29, 2015  — Sutor Technology Group Limited (the “Company” or “Sutor”) (Nasdaq: TOR), one of the leading China-based manufacturers and customized service providers for fine finished steel products used by a variety of downstream applications, today announced to attend the Global Industrial Supply Chain Fellowship Meeting to be held on August 1, 2015 by Jinying 365.com, a global industrial supply chain service platform, to share the Company’s business model of “Internet + Fine Finished Steel Customized Services” with industry peers.

During our business transformation into a fine finished steel customized service provider, we are aware that the Company should conform to the development trend of internet industry. Through opening online shops and launching mobile application for its fine finished products, the Company has increased its customer bases and improved customers’ service experience. At the upcoming Global Industrial Supply Chain Fellowship Meeting, we will share our achievements in customized services and discuss new development trends in steel industry with peer enterprises, so as to better improve the Company’s “Internet + Fine Finished Steel Customized Services” business model.

About Sutor Technology Group Ltd

Sutor is one of the leading China-based manufacturers and customized service providers for high-end fine finished steel products and welded steel pipes used by a variety of downstream applications. The Company utilizes a variety of in-house developed processes and technologies to convert steel manufactured by third parties into fine finished steel products, including hot-dip galvanized steel, pre-painted galvanized steel, acid-pickled steel, cold-rolled steel and welded steel pipe products. The Company also provides fee-based steel processing services to customers, including industrial peers. To learn more about the Company, please visit http://www.sutorcn.com/en/index.php.

Forward-Looking Statements

This press release includes certain statements that are not descriptions of historical facts, but are “forward-looking statements” in nature within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, among others, those concerning our expected financial performance, liquidity and strategic and operational plans, our future operating results, our expectations regarding the market for our products, our expectations regarding the steel market, as well as all assumptions, expectations, predictions, intentions or beliefs about future events.  You are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements.  These risks and uncertainties include, but not limited to, the factors mentioned in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2014, and other risks mentioned in our other reports filed with the Securities Exchange Commission (“SEC”).  Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system (EDGAR) at http://www.sec.gov.  The words “believe,” “expect,” “anticipate,” “project,” “targets,” “optimistic,” “intend,” “aim,” “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

For more information, please contact:

Investor Relations
Sutor Technology Group Limited
Tel: +86-512-5268-0988
Email: investor_relations@sutorcn.com

(UNIS) Introduces World’s First Instant Patch Pump for Insulin

Conference Call on Thursday, July 30 at 8:30 a.m. EDT*** Imperium™ combines therapeutic advantages of pumps with low cost and convenience of prefilled pens Enables Unilife and prospective insulin partners to penetrate large, growing Type 2 diabetes market

YORK, Pa., July 29, 2015  — Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced the introduction of the Imperium™ platform of instant patch pumps for insulin.

Imperium is a prefilled, disposable, multi-day wearable insulin pump that does not require filling or assembly by the patient. Because it is prefilled and pre-assembled like an insulin pen, only three intuitive steps are required to commence continuous subcutaneous insulin infusion, with on-demand bolus delivery available to the user via the simple push of a button. Imperium can include wireless connectivity systems, such as Bluetooth LE, to integrate with smartphone apps for patient reminders and status updates. With data connectivity available, healthcare providers could also have access to real-time or historic data to tailor the insulin therapy for each patient to achieve and maintain glycemic control.

Imperium is designed for supply to a select insulin partner or partners ready for filling and packaging using standard pharmaceutical processes, materials and equipment. Insulin partners can then sell the prefilled, fully-assembled device through existing commercial channels, with no sales, marketing, commercial development, reimbursement, and clinical support costs to Unilife. As a prefilled, high-precision device with a delivery resolution of 0.5µL, Imperium is suitable for use with high concentration insulins up to U-500.

Mr. Alan Shortall, Chairman and Chief Executive Officer of Unilife, said: “Imperium combines the therapeutic advantages of a pump with the low cost and convenience of a prefilled, disposable pen. By addressing specific unmet market needs and creating value for all diabetes stakeholders, it is set to empower millions of insulin-dependent patients to achieve and maintain glycemic control.”

“Unlike with traditional pumps or patch pumps, Imperium is designed to allow a selected insulin partner or partners to supply a complete basal-bolus insulin therapy directly to the patient under a single prescription at a price that is as attractive for reimbursement as prefilled pens. As a compact, ready-to-use and fully integrated insulin system requiring minimal steps for convenient, multi-day wear, it is well positioned to help improve patient adherence and generate positive healthcare outcomes.”

“In recognition of Imperium’s potential to penetrate large, growing markets, including Type 2 diabetes, that remain under-served due to device complexity, reimbursement constraints and high out-of-pocket-cost for patients, we expect to enter into a collaboration agreement with one or more interested parties that will support its long-term commercial supply with specific brands of insulin.”

The Company has scheduled a conference call for 8:30 a.m. U.S. EDT on Thursday, July 30, 2015 (Thursday, July 30, 2015, at 10:30 p.m. AEST), to update shareholders on its business activities and introduce the Imperium™ platform of instant insulin patch pumps.

The conference call and accompanying slide presentation will be broadcast over the Internet as a “live” listen-only Webcast.  An archive of the presentation and webcast will be available for 30 days after the call.  To listen, please go to: http://ir.unilife.com/events.cfm

A short video introducing Imperium is available on the Unilife website at www.unilife.com

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin delivery systems, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife’s global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

General: UNIS-G

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

(BLVDU) Stockholders Approve Acquisition Of AgroFresh Business From (DOW)

NEW YORK, July 29, 2015  — Boulevard Acquisition Corp. (“Boulevard”) (NASDAQ: BLVD, BLVDU, BLVDW), an entity sponsored by an affiliate of Avenue Capital Group, announced today that Boulevard’s stockholders have voted to approve all of the proposals related to the proposed acquisition from The Dow Chemical Company (“Dow”) (NYSE: DOW) of AgroFresh™, Dow’s post-harvest specialty chemical business, which will result in AgroFresh becoming a wholly owned subsidiary of Boulevard (the “Business Combination”). Boulevard’s Board of Directors had previously approved the Business Combination and recommended that its stockholders vote in favor of all of the proposals relating to the Business Combination.

In addition to approving the Stock Purchase Agreement, Boulevard’s stockholders approved proposals to (i) amend the amended and restated certificate of incorporation of Boulevard to, among other things, change Boulevard’s name to AgroFresh Solutions, Inc. and remove certain provisions related to Boulevard’s previous status as a blank check company; (ii) elect seven new directors to the board of Boulevard (Robert J. Campbell, Nance K. Dicciani, Gregory M. Freiwald, Thomas D. Macphee, Derek Murphy, Stephen S. Trevor and Macauley Whiting, Jr.); and (iii) approve the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan.

The Business Combination is expected to close on Friday, July 31, 2015. Upon closing, AgroFresh will become a wholly owned subsidiary of Boulevard and Boulevard will be renamed AgroFresh Solutions, Inc. as of that same date. Following the closing of the Business Combination, the combined company’s common stock and warrants will continue to be listed on NASDAQ’s Global Select Market under the ticker symbols “AGFS” and “AGFSW”, respectively.  The combined company’s units, which had been traded under the ticker symbol “BLVDU,” are expected to separate into their components of one share of common stock and one-half warrant to purchase a share of common stock on August 3, 2015.

None of Boulevard’s stockholders have elected to redeem any of their shares of Boulevard’s common stock for a portion of cash equal to their pro rata share of the aggregate amount on deposit in the trust account which holds the proceeds of Boulevard’s initial public offering.  The redemption period is now closed.

About Boulevard Acquisition Corp.
Boulevard Acquisition Corp. is a public investment vehicle formed by Avenue Capital Group for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.  Boulevard completed its initial public offering in February 2014, raising $220.5 million in cash proceeds.

Boulevard’s officers and certain of its directors are affiliated with Avenue Capital Group.  Avenue is an established global alternative investment firm founded in 1995. Avenue’s primary focus is investing in credit and other special situation investments in the United States, Europe and Asia.  Avenue has approximately $12.9 billion in assets under management as of May 31, 2015.  Additional information about Boulevard is available at www.boulevardacq.com.

Forward-Looking Statements
This news release may include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this news release that address activities, events or developments that Boulevard expects or anticipates will or may occur in the future are forward-looking statements and are identified with, but not limited to, words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions.  These statements are based on certain assumptions and analyses made by Boulevard in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.  Actual results may differ materially from those expressed herein due to many factors such as, but not limited to, the ability to satisfy closing conditions under the Stock Purchase Agreement, including approvals, and close the Business Combination, the performances of Boulevard and AgroFresh, the ability of the combined company to meet the NASDAQ Global Select Market’s listing standards, including having the requisite number of stockholders, and the risks identified in Boulevard’s prior and future filings with the SEC (available at www.sec.gov), including the definitive proxy statement filed on July 16, 2015 with the SEC in connection with the proposed transaction and Boulevard’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. These statements speak only as of the date they are made and Boulevard undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances which arise after the date of this news release.  Investors are cautioned that forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of AgroFresh, Boulevard and the combined company after completion of the business combination are based on current expectations that are subject to risks and uncertainties.

Contact for Boulevard Acquisition Corp.:

Todd Fogarty
Kekst and Company
+1 (212) 521-4854
todd-fogarty@kekst.com

(CATB) To Present CAT-2000 Program of SREBP Modulators for Hyperlipidemias

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Catabasis will present an overview of the CAT-2000 program, the Company’s product candidate series targeting the Sterol Regulatory Element-Binding Protein, or SREBP, pathway for the potential treatment of hyperlipidemias, at the Kern Lipid Conference. The Kern Lipid Conference will be held August 3 – 5, 2015, in Vail, Colorado at the Vail Marriott Mountain Resort.

• Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will give a presentation titled “The CAT2000 program: Oral Modulators of SREBP in Development for Hyperlipidemias.” The presentation will take place on Monday, August 3, 2015, at 3:20 pm local time in the Grand Ballroom, Salon F-J.

About CAT-2000

The CAT-2000 series are molecules engineered by Catabasis using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform to inhibit the maturation of Sterol Regulatory Element-Binding Protein (SREBP) and reduce the expression of key proteins involved in LDL-C and triglyceride metabolism. The CAT-2000 series include CAT-2054, CAT-2003, and other conjugates. In the CAT-2000 series, Catabasis’ development priority is CAT-2054 for the treatment of hypercholesterolemia.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company’s technology and pipeline of drug candidates, please visit www.catabasis.com.

(CDRB) to Acquire ThinOps Resources

(IPWR) KACO new energy Resell Agreement, Converters & Storage Systems To Use Ideal’s Tech

Ideal Power’s Products to Be Marketed and Sold Under the KACO Brand in North and Central America

(OGEN) Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study

Oragenics, Inc. (NYSE MKT: OGEN) and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, announced today positive data on multiple compounds from Oragenics’ Mutacin 1140 (“MU1140”) lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate. The compounds were subjected to a standardized “proof of concept” animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomycin positive control.

Lantibiotics are a class of antibiotics with a novel mechanism of action active against several multi-drug resistant infectious agents. Through its Exclusive Channel Collaboration (“ECC”), Oragenics has utilized Intrexon’s proprietary bio-engineering capabilities to develop its MU1140 analog pipeline which could provide an important new tool in the fight against global bacterial antibiotic resistance.

The tested compounds were selected based on important compound characteristics including, but not limited to: drug activity (based on minimum inhibitory concentration) equal or better than “standard of care” drugs against certain drug-resistant bacteria, safety, toxicity, stability, and manufacturability. The study specifically evaluated compound efficacy as measured by survivability, amounts of C. difficile colony forming units, and toxin levels. Overall several compounds demonstrated promising results, and Oragenics’ new lead clinical candidate achieved a 100% survival rate throughout the entire study in contrast to a 33% survival rate for the vancomycin (current standard of care) positive control. There was a 0% survival rate for the placebo control group.

Frederick Telling, Ph.D., Chairman of the Board of Oragenics said, “These test results represent a significant development and we are delighted to share this progress as we continue our efforts to develop lantibiotics, a new therapeutic class of antibiotics, with our collaborator Intrexon to combat the growing problem of resistance to existing therapeutics.” Dr. Telling added, “We remain on-track for our previously disclosed expectation of pre-IND meetings with the U.S. Food and Drug Administration in the fourth quarter. This in vivo efficacy data represents a significant step forward in the development path undertaken by Oragenics.”

Samuel Broder, M.D, Senior Vice President and Head of Intrexon’s Health Sector, stated, “We are very pleased that the suite of Intrexon technologies and proprietary industrial processes has facilitated the development of novel lantibiotics by our ECC partner, Oragenics. This is an important area of much needed new antibiotic development.”

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established three exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon’s proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora both in the United States and through the use of distributors in locations outside of the United States. For more information about Oragenics, visit www.oragenics.com.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.

Trademarks

Intrexon and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

(AQXP) Update on BPS/IC Phase 2, Second Quarter Financial Results

VANCOUVER, British Columbia, July 28, 2015  — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will provide an update on results from secondary endpoints from its recently completed Phase 2 LEADERSHIP randomized clinical trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Aquinox will also provide a general business update and report second quarter 2015 financial results on Thursday, August 6^th, 2015 after close of U.S. financial markets.

Aquinox will host a conference call and live webcast on Thursday, August 6^th, 2015 at 4:45 PM (ET) / 1:45 PM (PT). Presentation slides will accompany the webcast and will be posted to the Aquinox website following completion of the call.

Conference Call and Webcast Details:

Date: Thursday, August 6^th, 2015 Time: 4:45 PM (ET) / 1:45 PM (PT).
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 96372657
Webcast URL: http://edge.media-server.com/m/p/4b67r6k9

The live webcast may be accessed through the “Events & Presentations” page in the “Investor Relations” section of the company’s website at www.aqxpharma.com. The archived webcast will also be available on Aquinox‘s website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About AQX-1125

AQX-1125, Aquinox’s lead drug candidate, is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. By increasing SHIP1 activity, AQX-1125 accelerates a natural mechanism that has evolved to maintain homeostasis of the immune system and reduce immune cell activation and migration to sites of inflammation. AQX-1125 has demonstrated preliminary safety and favorable drug properties in multiple preclinical studies and clinical trials. Aquinox is currently developing AQX-1125 as an oral, once daily treatment in bladder pain syndrome/interstitial cystitis. In addition, Aquinox is exploring AQX-1125 for atopic dermatitis in its ongoing KINSHIP Phase 2 trial with top line data expected by Q1 2016.

About Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox’s lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.

Investor Contact:

Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
ir@aqxpharma.com

Communications Contact:

Heather Savelle
Vice President
MacDougall Biomedical Communications
781.235.3060
aquinox@macbiocom.com

(RADA) Selected for Evaluation by a Branch of the US Military

RADA’s Tactical Multi-Mission Hemispheric Radar Provides Volume Surveillance and Detection of Multiple Threat Types, Including UAVs, Manned Aircraft, Mortars and Rockets

NETANYA, Israel, July 28, 2015  — RADA Electronic Industries of Netanya, Israel (NASDAQ:RADA) announces the purchase of a Multi-Mission Hemispheric Radar (MHR), by a branch of the US military for testing and evaluation of its capabilities. This purchase, which is the first by this branch of the US military, follows previous purchases of MHRs by leading US integrators and end users for similar purposes. The MHR will be delivered before the end of 2015.

The MHR — an S-Band, software-defined, Pulse-Doppler, active electronically scanned array radar — has sophisticated beam forming capabilities and advanced signal processing, provides multiple missions on each radar platform, and offers unprecedented performance-to-price ratio. It is compact and mobile, delivering ideal organic, tactical surveillance solutions for force and border protection applications such as counter rockets and mortars, counter unmanned aerial systems, ground moving target indicator and air surveillance.

Zvi Alon, RADA’s CEO, remarked, “We are very pleased with the growing interest in our radars by the US market, which we believe will be one of the most important markets for our radar technology.”

About RADA

RADA Electronic Industries Ltd. is an Israel-based defense electronics contractor. The Company specializes in the development, production, and sale of tactical land radars for force and border protection, inertial navigation systems for air and land applications, and avionics systems and upgrades.

CONTACT: RADA
         Dov Sella (CBDO)
         Tel: +972-9-892-1111
         mrkt@rada.com
         www.rada.com

(CAPN) $10 Million At-the-Market Firm Commitment Stock Purchase Agreement

Company Advancing Promising Treatment for Cluster Headache, Trigeminal Neuralgia and Allergic Rhinitis

REDWOOD CITY, Calif., July 27, 2015  — Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel products based on its proprietary technologies for precision metering of gas flow, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”). Under the new agreement, Capnia has the right to sell up to $10 million in value of its common stock to Aspire Capital, subject to certain terms and conditions, over a two-year period.  The agreement represents a strategic tool that provides Capnia with important capital to fund the development of its therapeutics pipeline.

“Our promising therapeutics pipeline is a renewed focus at Capnia and we have recently made significant advances with these programs, in particular with cluster headache where we recently entered the clinic,” said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. “This financing with Aspire provides us with strategic leverage, financial flexibility, and an excellent financing alternative as it enables us to raise capital on an as-needed basis.  Having this ready access to capital provides us a stronger financial position as we continue to execute, not only on the commercialization of CoSense, but on the near term value drivers in our therapeutic business.”

Therapeutics Pipeline Overview

Capnia was originally founded on its innovative therapeutic technology that uses nasal, non-inhaled CO₂ (nasal CO₂), delivered at a low-flow rate into the nasal cavity. We believe that potential indications include alleviation of symptoms of allergies as well as trigeminally-mediated pain disorders such as cluster headache, migraine and trigeminal neuralgia (TN).  Capnia has completed multiple clinical trials for the treatment of the symptoms of allergic rhinitis as well as conditions such as migraine using this technology.  The use of Capnia’s nasal CO₂ product for the treatment of cluster headache, migraine and TN is supported by data demonstrating that CO₂ may inhibit sensory nerve activation, subsequent release of neuropeptides and alleviate trigeminally-mediated pain.

Nasal CO₂ for the Treatment of Cluster Headache – In January 2015, Capnia partnered with Clinvest® to develop a therapeutic product for the treatment of cluster headache. In July 2015, Capnia announced the commencement of a pilot clinical trial evaluating nasal CO₂ in approximately 25 patients with episodic cluster headaches. Roger K. Cady, M.D., founder of the Headache Care Center and Chief Executive Officer of Clinvest, will serve as principal investigator for the investigator-sponsored trial.  Capnia expects to report top-line data from this trial in 2016.

Nasal CO₂ for the Treatment of Trigeminal Neuralgia – In December 2014, Capnia submitted an application to the U.S. Food and Drug Administration (FDA) requesting Orphan Drug Designation for nasal CO₂ for the treatment of trigeminal neuralgia (TN).  In March of 2015, Capnia received a response from the FDA and is continuing its discussions with the FDA regarding Orphan Drug Designation for its nasal CO₂ technology in this indication. Capnia expects to initiate a pilot clinical trial evaluating nasal CO₂ in TN in Fall 2015.

Nasal CO₂ for the Treatment of Allergic Rhinitis (Serenz™) – To date, Capnia has conducted studies with nasal CO₂ in 975 patients across six randomized, controlled clinical trials. In the clinical trials to date, nasal CO₂ has shown a large effect size, an onset of effect within 30 minutes, and is well-tolerated. Capnia expects to clarify the regulatory approval pathway for allergic rhinitis in the U.S. with the FDA by the end of 2015, and subsequently, will seek to secure partnership or continue development.

Aspire Capital Financing

Under the terms of the common stock purchase agreement, Capnia has the right to sell up to $10 million in value of its common stock to Aspire Capital, subject to certain terms and conditions, over a two-year period. Other key terms of the agreement are:

• Capnia will control the timing and amount of any sale of common stock to Aspire Capital;
• Aspire Capital has no right to require any sales of Common Stock by Capnia, but is obligated to make purchases as Capnia directs, in accordance with the terms of the purchase agreement;
• There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement; and
• The purchase agreement may be terminated by Capnia at any time, at its discretion, without any additional cost or penalty.

A complete and detailed description of the purchase agreement and related registration rights agreement will be set forth in the Company’s Current Report on Form 8-K filed with the SEC.

About Capnia

Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia’s lead product CoSense® is based on the Sensalyze™ Technology Platform. It is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the European Union. CoSense is used for the monitoring of CO from internal sources (such as hemolysis, a dangerous condition in which red blood cells degrade rapidly), as well as external sources (such as CO poisoning and smoke inhalation). The initial target market is newborns with jaundice that are at risk for hemolysis, comprising approximately three million births in the U.S. and European Union. Capnia’s proprietary therapeutic technology uses nasal, non-inhaled CO₂ and is being evaluated to treat the symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development and clinical trials and that entering into this agreement will further our therapeutic business.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia’s Form 10-K filed with the Securities and Exchange Commission on March 13, 2015, including under the caption titled “Risk Factors.” Capnia expressly disclaims any intent or obligation to update these forward looking statements, except as required by law.

CONTACT: Investor Relations Contact:
         Michelle Carroll/Susie Kim
         Argot Partners
         (212) 600-1902
         michelle@argotpartners.com
         susan@argotpartners.com

(MNOV) FDA Approval of Phase 2 Protocol for MN-001

LA JOLLA, Calif., July 27, 2015  — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) has approved a second protocol for a clinical trial evaluating MN-001 (tipelukast) for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased to have successfully completed the FDA review period and look forward to initiating patient enrollment shortly. The safety and efficacy data from this trial will be important to our overall development efforts targeting NASH and should be complementary to efforts underway. In previous clinical trials and preclinical studies, serum triglyceride levels were reduced in MN-001-treated groups. It is well known that NASH patients often have elevated serum lipid levels, one of the factors that contribute to cardiovascular disease. Recent studies have confirmed that cardiovascular disease is the single most important cause of mortality in this patient population. Importantly, MN-001’s anti-fibrotic properties combined with its potential to reduce triglyceride levels in NASH patients offers a novel approach to the treatment of NASH.”

About the Study Design

The Phase 2 trial is a single-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in subjects with nonalcoholic steatohepatitis (NASH) and hypertriglyceridemia. Eligible subjects will consist of males and females ranging in age from 21 to 65 years old, inclusive. To be eligible, subjects must have a histologically confirmed diagnosis of NASH within 6 months prior to the baseline visit and an elevated serum triglyceride (> 150 mg/dL) during the Screening Phase. Approximately twenty (20) qualifying subjects will be given MN-001 250 mg orally administered once a day for the first 4 weeks and will be given MN-001 250 mg twice a day for an additional 8 weeks. Overall, the study timeline consists of a Screening Phase (up to 4 months) followed by a Treatment Phase (12 weeks), and a Follow-up visit (within 1 week after the last dose).

The primary efficacy endpoints of the study are to evaluate the effect of MN-001 on 1) Triglyceride levels in NASH subjects with hypertriglyceridemia, and 2) Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia. Secondary endpoints include safety and tolerability of MN-001, PK profile of MN-001/MN-002 (by-product of MN-001), effects of MN-001 on HDL-C, LDL-C, and total cholesterol level, and effects of MN-001/002 on liver enzymes and percent fat in liver assessed using MRI at Week 12.

Earlier this year, the FDA granted Fast-Track designation to MN-001 for the treatment of NASH with fibrosis.  Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA’s Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development.  Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.

About Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a condition in which there is fat in the liver along with inflammation and damage to liver cells. NASH is a common liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol. According to the U.S. National Digestive Diseases Information Clearinghouse (NDDIC), NASH prevalence in the U.S. is 2-5%, and an additional 10-20% of Americans have “fatty liver.” The underlying cause of NASH is unclear, but it most often occurs in people who are middle-aged and overweight or obese. Many patients with NASH have elevated serum lipids, diabetes or pre-diabetes. Progression of NASH can lead to liver cirrhosis. Liver transplantation is the only treatment for advanced cirrhosis with liver failure. At this time, there is no treatment for NASH.

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.

Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and is considered generally safe and well-tolerated. Importantly, in these studies, reduction of serum triglyceride was observed for those treated with MN-001 in healthy volunteers and target populations.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., methamphetamine dependence and opioid dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001 and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001 and MN-029, risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2014 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

CONTACT: INVESTOR CONTACT: 
         Geoff O'Brien
         Vice President
         MediciNova, Inc.
         info@medicinova.com

(CPXX) to Present on Fixed-Ratio Nanomedicines

EWING, N.J., July 27, 2015  — Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, announced that Dr. Lawrence Mayer, Founder, President and Chief Scientific Officer, will chair and present at a mini-symposia today, July 27, 2015, at 10:00am ET, at the 42^nd Annual Meeting and Exposition of the Controlled Release Society.

The mini-symposia will discuss Therapeutic Cancer Nanomedicines and Dr. Mayer’s presentation is titled, “Development of Fixed-Ratio Anticancer Drug Combination Nanomedicines That Markedly Improve Efficacy and Survival Outcomes.”

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity.  CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor.  Celator’s pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory.  The company is advancing the CombiPlex platform and broadening its application to include molecularly targeted therapies and epigenetic modulators.

For more information, please visit Celator’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and development programs, the efficacy and commercial potential of our drug candidates, and our performance and achievements to differ significantly from those expressed or implied by the forward-looking statements.  Celator undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator’s Form 10-K for the year ended December 31, 2014 and other filings by the company with the U.S. Securities and Exchange Commission.

CONTACTS:
Media:
Mike Beyer
Sam Brown, Inc.
773-463-4211
beyer@sambrown.com

Investors:
Adam Krop
The Trout Group
646-378-2963
akrop@troutgroup.com

(CYRX) Portfolio of Temperature-Managed Clinical Programs Expands to 45 Trials

LAKE FOREST, Calif., July 27, 2015  — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, with markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, is now supporting approximately 45 clinical trials. The majority of these trials are regenerative therapies, including an array of CAR T-cell therapies. In total, these immunotherapy trials are expected to contribute as much as $150 million of revenue for Cryoport over the next five years.

The cryogenic logistics demands to support these therapies throughout their clinical trial phases increase over the life of the trial as data is collected and processed and the trial population size is expanded. Upon successful completion and approval by the U.S. Food and Drug Administration, these therapies are commercialized, providing a “hockey stick” shape to the demand curve for Cryoport’s solutions.

Jerrell Shelton, President and CEO of Cryoport, stated, “Our 5-year cumulative estimate of $150 million of revenue associated with these 45 clinical trials is based on market data and customer development schedules. We expect the momentum we have seen in the number of clinical trials supported by Cryoport to continue at its current strong pace, driving higher revenue contributions as new customers contract for our validated cryogenic logistics solutions. It is important to remember that this estimate is at present; the development of immunotherapies is only just beginning and has enormous growth potential.”

Immunotherapies are in their infancy and, in recent months, Cryoport has been aggressively expanding its support of all immunotherapies including CAR T-cell and regenerative therapies. Previously, the Company announced relationships with Kite Pharma, Capricor Therapeutics, Cellerant Therapeutics, Caladrius Biosciences et al.

It has been reported that the total biologics market is $289 billion, with a growth rate of 10.8% per year. Cryoport estimates that cryogenic cold chain logistics is growing at 14% per year, reflecting the disproportionate growth of the market requiring cryogenic logistics. Clinical trials supported by Cryoport include diverse therapeutic areas such as oncology, autoimmune disease, Parkinson’s, and congestive heart failure. These trials are in Phases I, II, and III and the geographic reach includes the United States, Europe, Japan, Australia, South America, Africa, as well as multiple locations throughout Asia.

Mark W. Sawicki, Ph.D., Chief Commercial Officer of Cryoport, commented, “Cryoport is uniquely positioned to support the rapidly developing immunotherapy segment of the life sciences industry through its advanced cryogenic logistics solutions.  We have been building a strong reputation within the scientific community as well as the broader life sciences industry through our strong performance as a premier partner that is able to manage the complexities of getting autologous and allogeneic therapies from manufacturing centers to patients in the specified conditions required.”

Mr. Shelton added, “We are pleased with the acceptance of our solutions by the scientific and healthcare communities. Such acceptance, demonstrated through their respective commitment to our cryogenic logistics platform, is further acknowledgment of our growing reputation for reliability with our validated solutions. Cryoport is steadfast in its support of the new therapy areas and expects to continue to partner with cutting edge life sciences companies to support their cryogenic logistics requirements and clinical portfolios in the coming months.”

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.

To download Cryoport’s investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or  Android mobile device.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company’s cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

(SAEX) Announces New $47 Million Ocean-Bottom Marine Project Award

HOUSTON, July 27, 2015  — SAExploration Holdings, Inc. (NASDAQ:SAEX) (OTCBB:SAEXW) today announced a new project award for ocean-bottom marine seismic data acquisition services valued at approximately $47 million. The Company expects to execute the project during the second half of 2015.

This project will be performed using ocean-bottom nodal seismic recording technology equipped to successfully operate in transition zones and water depths ranging from zero to 3,000 meters deep. SAE will utilize currently available equipment and personnel to execute the project with no new capital expenditures required.

Brian Beatty, President and CEO of SAE, commented, “We are excited to have secured another ocean-bottom marine project. This will allow us to build on our continued success in this market, as evidenced by our recently completed major deep water program in Southeast Asia. As new nodal technology replaces older cabled systems, it is our belief the ocean-bottom marine seismic market will continue to present meaningful opportunities to SAE. We view our ability to win new business as a key testament to the strength of our business model and the attractiveness of our markets.”

About SAExploration Holdings, Inc. 

SAE is an internationally-focused oilfield services company offering a full range of vertically-integrated seismic data acquisition and logistical support services in remote and complex environments throughout Alaska, Canada, South America, Southeast Asia and Africa. In addition to the acquisition of 2D, 3D, time-lapse 4D and multi-component seismic data on land, in transition zones and offshore in depths up to 3,000 meters, SAE offers a full suite of logistical support and in-field processing services, such as program design, planning and permitting, camp services and infrastructure, surveying, drilling, environmental assessment and reclamation and community relations. SAE operates crews around the world, performing major projects for its blue-chip customer base, which includes major integrated oil companies, national oil companies and large independent oil and gas exploration companies. Operations are supported through a multi-national presence in Houston, Alaska, Canada, Peru, Colombia, Bolivia, Brazil, New Zealand and Malaysia. For more information, please visit SAE’s website at www.saexploration.com.

The information in SAE’s website is not, and shall not be deemed to be, a part of this notice or incorporated in filings SAE makes with the Securities and Exchange Commission.

Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the federal securities laws. These statements can be identified by the use of words or phrases such as “believes,” “estimates,” “expects,” “intends,” “anticipates,” “projects,” “plans to,” “will,” “should” and variations of these words or similar words.  These forward-looking statements may include statements regarding SAE’s financial condition, results of operations and business and SAE’s expectations or beliefs concerning future periods. These statements are subject to risks and uncertainties which may cause actual results to differ materially from those stated in this release. These risks and uncertainties include fluctuations in the levels of exploration and development activity in the oil and gas industry, intense industry competition, a limited number of customers, the need to manage rapid growth, delays, reductions or cancellations of service contracts, operational disruptions due to seasonality, weather and other external factors, crew productivity, the availability of capital resources, high levels of indebtedness, substantial international business exposing SAE to currency fluctuations and global factors including economic, political and military uncertainties, the need to comply with diverse and complex laws and regulations, and other risks incorporated by reference to SAE’s filings with the Securities and Exchange Commission. Certain risks and uncertainties related to SAE’s business are or will be described in greater detail in SAE’s filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. Except as required by applicable law, SAE is not under any obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

Contact

SAExploration Holdings, Inc.
Ryan Abney
Vice President, Capital Markets & Investor Relations
(281) 258-4409
rabney@saexploration.com